Saturday, Apr 20 2024 | Time 02:36 Hrs(IST)
image
Business EconomyPosted at: Sep 22 2020 8:27PM


Biorasi Commended by Frost & Sullivan for its Full-service Offering to Drive Rare Disease Patient Recruitment for CROs

SANTA CLARA, California, Sept. 22, 2020 /PRNewswire/ -- Based on its recent analysis of the North American contract research organization (CRO) market, Frost & Sullivan recognizes Biorasi, LLC with the 2020 North American Entrepreneurial Company of the Year Award. Biorasi's milestone-based, patient-centric approach to driving patient recruitment for rare diseases, hard-to-recruit indications, and clinical trial rescues differentiate it from its peers. Its special expertise in neurology, nephrology, dermatology, and oncology as well as relationships with global site networks across the Americas, Europe, and Asia-Pacific allow it to access a wide patient base and enroll participants rapidly, and they provide their partners with real-time, on-demand visibility into the progress of their studies.
"Biorasi specializes in designing the right clinical strategies for a particular indication quickly and finding suitable sites and patients to participate in studies for those indications," said Khushbu Jain Industry Analyst. "Powered by its proprietary Talosᵀᴹ trial management system, Biorasi advances technology-enabled protocol optimization programs, improving clinical trial performance, and success rates. Furthermore, as an expert in digital therapeutic trials, it aids in clinical validation, regulatory approval, and payer reimbursement."
Biorasi's partnership-based model is particularly valuable to innovative science-driven but smaller drug and device developers that rely heavily on external partners to take research from labs to markets and are especially sensitive to price hikes and timeline delays. Its patient-centric approach to trial execution involves facilitating patient recruitment for rare disease research by leveraging its relationships with advocacy groups, national registries, and global site networks Furthermore, it harnesses its partnerships with data science enterprises to create heat maps for specific illnesses, allowing pharmas to locate patient clusters and rapidly target trial recruitment efforts.
Beyond solving patient recruitment and engagement challenges, Biorasi addresses issues related to protocol design, clinics, and delays due to new regulations. Its medical and scientific experts design trial protocols as per the rapidly evolving regulatory environment to support Software-as-a-Medical-Device. Its clinical trial optimization programs are quick, intelligent, and integrated with company experts and technology to improve trial performance, especially in the DTx area. Combined with drug therapies, Biorasi aids in advancing remote monitoring, adherence, telemedicine, and disease-specific digital tools as an alternative to medication, especially in behavioral health.
"Biorasi engages early with its clients to develop long-term customer relationships," noted Jain. "Its flexibility, transparency, and milestone-based pricing demonstrate its commitment to customers. By focusing on the industry's highest growth areas, namely oncology and neurology, it has established itself as an emerging leader in the CRO market."
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in products and technologies, leadership in customer value as well as speed in response to market needs. The award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Harley Gadomski
P: 12104778469
E: [email protected]
About Biorasi, LLC
Biorasi is a customer-focused, full-service, contract research organization (CRO) that leverages speed and agility in the execution of clinical trials to maximize speed-to-market for its sponsors – all powered by our proprietary TALOS™ project management system. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market. To learn more, contact Biorasi at [email protected] / (786) 388-0700.

(Disclaimer--Features may vary depending on the regions; subject to change without notice.)
Please log in to get detailed story.
Tags: #Biorasi Commended by Frost & Sullivan for its Full-service Offering to Drive Rare Disease Patient Recruitment for CROs
More News

"CSIR-IICT and BHEL partners to advance clean fuel technology: MoU signed on CO2 to DME"

19 Apr 2024 | 7:23 PM

Hyderabad, April 19 (UNI) The Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) and Bharat Heavy Electricals Limited (BHEL) Corporate R&D have forged a partnership to develop technology for capturing and converting carbon dioxide (CO2) to Dimethyl Ether (DME) through direct catalytic conversion.

see more..

Amara Raja Infra Wins Greenko’s 700MWp solar project in AP

19 Apr 2024 | 6:41 PM

Hyderabad, Apr 19 (UNI) Amara Raja Infra Private Limited (ARIPL), part of the $1.75 billion Amara Raja Group, on Friday announced it has secured a solar BoS (Balance of System) project of 500MW/700MWp from Greenko.

see more..
Sensex recovers 600 points on heavy buying on last day of week

Sensex recovers 600 points on heavy buying on last day of week

19 Apr 2024 | 5:34 PM

Mumbai, April 19 (UNI) Snapping a losing streak of last four sessions, the BSE Sensex on Friday bounced back 599.34 points to close at 73088.33 on expectation of minimal escalation of tension between Israel and Iran.

see more..

19 Apr 2024 | 5:24 PM

Mumbai, Apr 19 (UNI) IT major Wipro on Friday reported 7.80% year-on-year dip in consolidated net profit at Rs 2,834.6 crore for January-March quarter (Q4) of the financial year 2023-24.

see more..
Rupee up 8 paise against USD

Rupee up 8 paise against USD

19 Apr 2024 | 5:05 PM

Mumbai, April 19 (UNI) The Rupee on Friday ended positive at 83.47, rising 8 paise against the USD on selling US Dollar by bankers and exporters, dealers at the Foreign exchange said.

see more..
image